Connect with a Global Network of Leading Myopathy Drug Developers, Build Strategic Partnerships & Drive Success
As more companies move into the muscular drug development space and pharma investment accelerates, evidenced by multi-billion dollar spends from the likes of Servier and Novartis. In turn, the demand for complex preclinical models, digital endpoint support and muscle-specific imaging and biomarker services is growing.
The challenges for rare disease trial design and drug development are unique, with decision makers looking for innovative 2D and 3D preclinical models with high translatability and tools to accurately measure and quantify muscle function. With limited patient pools and biopsy samples available, pharma and biotech are seeking precision and specialist expertise throughout every phase of the drug development process.
The inaugural Muscular Disorders Drug Development Summit offers a unique platform to showcase your solutions to a global network of leading myopathy drug developers revolutionizing preclinical, translational and clinical programs in 2027.
What to Expect?
Distinguish Yourself as Expert Specialist Solution Providers
Demonstrate how your capabilities support the optimization of rare disease clinical trial design, helping developers navigate complexity, novel strategies, and accelerate drug development.
Connect with Decision-Makers to Generate Commercial Opportunities
Engage with senior leaders actively tackling challenges across preclinical, translational and clinical areas - the teams responsible for selecting partners who can support specialized development in practice.
Align Your Brand with the Future of Next-Generation Muscular Therapies
Position your organization at the center of an industry shift where gene therapies and traditional biomarkers aren’t the only option. Showcase how your solutions enable programs that are built for the future muscular disorder therapeutics.
Turn Conversations into Long-Term Partnerships
Build meaningful connections with organizations actively looking for partners to support complex rare disease trials, helping you move beyond visibility to become a trusted contributor to their delivery strategy.
Covering the Full Spectrum of Muscular Disorders Drug Development
From Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD) to myotonic dystrophy (DM1), limb-girdle muscular dystrophy (LGMD), Pompe disease, and related myopathies, the Muscular Disorders Drug Development Summit brings together leaders driving innovation across the muscular disease landscape. Explore shared development challenges, indication-specific insights, and opportunities to accelerate therapeutic advancement across multiple disease areas.
Key Services & Solutions
Our audience of decision makers across muscular disorder programs are actively seeking partners who specialize in:
Preclinical CROs & Disease Models
Supporting biopharma to evaluate the safety, efficacy, biodistribution and pharmacokinetics of novel therapeutics before clinical development. As gene-therapies, RNA-targeting approaches, and next-generation modalities advance across muscular dystrophies, developers are seeking CROs with specialized neuromuscular expertise and translational disease models. From animals to human-relevant systems such as muscle-on-a-chip, sponsors need partners who can generate predictive data, improve clinical translation and help de-risk development decisions.
Clinical CROs
Designing, implementing and executing clinical trials across rare muscular dystrophies while navigating the complexities of small patient populations and evolving regulatory expectations. Developers are looking for CROs with expertise in neuromuscular diseases, global trial operations, patient recruitment and natural history-informed study design. Partners who can work seamlessly across functions and manage compliance requirements are critical to accelerating development and working towards clinical success.
Digital & Functional Biomarker Services
Providing innovative tools and technologies to measure disease progression, treatment response and muscle function across muscular dystrophies. As sponsors look beyond traditional clinical endpoints, demand is growing for providers who can measure digital biomarkers with wearable devices, and remote monitoring solutions alongside established functional assessments.
Audience Composition
Company Type
Attendee Seniority
Attending Companies Include
Explore Tailored Partnership Opportunities
Explore a range of sponsorship opportunities designed to position your organization at the forefront of Muscular Disorder Drug Development. Whether you provide preclinical models, CRO services, biomarker and endpoint solutions, clinical technologies, manufacturing support or patient engagement services, these opportunities enable you to connect directly with the teams responsible for driving therapeutic innovation.
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Angus Booth
Partnerships Director
Position Your Brand at the Forefront of Muscular Disorder Innovation
Showcase your expertise alongside the companies and leaders advancing the next generation of therapies for muscular disorders.
Connect with the Decision Makers Shaping the Field
Engage directly with senior leaders during dedicated meeting breaks and structured networking opportunities.
Demonstrate the Value of Your Solutions
Explore our bespoke sponsorship options including branding, presenting, and exhibiting to build a package tailored to you and your company's goals.